Vaccines for Children (VFC) Program Update: Current COVID-19 Vaccine Inventory Guidance

Please review the latest information regarding the seasonal COVID-19 and influenza vaccine supply recommendations.

Revocation of Emergency Use Authorization for 2024-2025 COVID-19 Vaccine Products

On August 27, 2025, the Food and Drug Administration (FDA) revoked the Emergency Use Authorization (EUA) for the following COVID-19 vaccines that were used during the 2024-2025 respiratory season:

  • Pfizer-BioNTech COVID-19 Vaccine.
  • Moderna COVID-19 Vaccine.
  • Novavax COVID-19 Vaccine.

The COVID-19 vaccines authorized for the previous 2024-2025 respiratory season whose EUAs have been revoked should no longer be administered to patients.

  • These VFC-supplied COVID-19 vaccines should be removed from storage units immediately, even if they are not expired, and returned to McKesson using the VFC vaccine transfer form to initiate the return label request process.
  • The ODH VFC transfer form can be found here: Vaccines for Children Transfer Form | Ohio Department of Health.
  • Please note that only federal-supplied vaccines (VFC and Adult Programs) are to be returned to McKesson for a vaccine excise tax credit.

 

Ohio VFC Program - COVID-19 Vaccine EUA Revocations

  • 2024-2025 Pfizer/BioNTech; 3mcg/0.3mL multi-dose vial; 6 months - 4 years; 59267-4426-02
  • 2024-2025 Pfizer/BioNTech; 10mcg/0.3mL single-dose vial; 5 years - 11 years; 59267-4438-02
  • 2024-2025 Moderna; Prefilled syringes; 6 months - 11 years; 80777-0291-80
  • 2024-2025 Novavax; Prefilled syringes; 12 years +; 80631-0107-10

Details about these revocations can be found online at Emergency Use Authorization--Archived Information | Food and Drug Administration.

2025-2026 COVID-19 Vaccine Recommendations and Ordering

On August 27, 2025, the U.S. FDA approved COVID-19 vaccines for the 2025–2026 season manufactured by Moderna, Pfizer, and Sanofi/Novavax. Information regarding the newly approved formulations of COVID-19 vaccines can be found here: Vaccines Licensed for Use in the United States | Food and Drug Administration.

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has not yet issued specific guidance for clinicians regarding the use of the newly approved COVID-19 vaccine formulations.

The ODH Immunization Program will share information about 2025-2026 COVID-19 vaccine recommendations and availability through the VFC Program when it becomes available.

Some healthcare providers may have remaining stock of the 2024-2025 COVID-19 vaccine for ages 12 years and older during this seasonal vaccine transition period. CDC has recommended that patients vaccinated for the 2025–2026 season receive vaccine licensed for use in the 2025–2026 season, rather than remaining vaccines licensed from the 2024–2025 season.

2025-2026 Influenza Vaccine Availability

  • The VFC influenza vaccine prebook window closed on August 31, 2025. Approximately 89% of Ohio VFC providers submitted a flu vaccine order during the prebook period.
  • Since the 2025-2026 flu vaccine products are now available at the federal vaccine distribution center, the ODH VFC Program has processed the first allocations of flu vaccine. Providers can anticipate their initial deliveries of prebooked flu vaccine to arrive as early as this week.
  • Providers who did not place a prebook order for flu vaccine can request a paper order form from the ODH VFC Program by calling 1-800-282-0546.
  • Recommendations for the use of 2025-2026 influenza vaccine were passed by the Advisory Committee on Immunization Practices (ACIP) at the June 2025 meeting. These recommendations were published in the Morbidity and Mortality Weekly Report Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025–26 Influenza Season on August 28, 2025.